OAM
NBIX icon

Optimal Asset Management’s Neurocrine Biosciences NBIX Stock Holding History

Optimal Asset Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$2.18M Buy
22,773
+46
+0.2% +$4.34K 0.27% 138
2021
Q2 		$2.21M Hold
22,727
– – 0.26% 143
2021
Q1 		$2.21M Buy
22,727
+6,400
+39% +$671K 0.29% 133
2020
Q4 		$1.56M Hold
16,327
– – 0.22% 160
2020
Q3 		$1.57M Buy
16,327
+4,951
+44% +$573K 0.23% 144
2020
Q2 		$1.39M Sell
11,376
-1,273
-10% -$141K 0.23% 150
2020
Q1 		$1.09K Buy
+12,649
New +$1.24M 0.1% 280

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
EVM
Eaton Vance Management Boston, Massachusetts $67.5B AUM 11.44% 1-Year Est. Return

Optimal Asset Management's NBIX Position: Q3 2021 in Review

Optimal Asset Management increased its Neurocrine Biosciences (NBIX) stake by 0.2% in Q3 2021, buying an estimated $4.34K and bringing the position to 22,773 shares worth $2.18M. The position accounts for 0.27% of the portfolio, ranked #138.

Optimal Asset Management first reported a position in NBIX in Q1 2020 and has held it in 7 quarters since. The position peaked at $2.21M in Q2 2021. 395 funds tracked by Wall St. Rank hold NBIX as of Q3 2021.

  • Optimal Asset Management held 22,773 shares of Neurocrine Biosciences worth $2.18M as of Q3 2021.
  • Optimal Asset Management bought 46 Neurocrine Biosciences shares in Q3 2021, an estimated $4.34K.
  • Neurocrine Biosciences made up 0.27% of Optimal Asset Management's portfolio in Q3 2021, its #138 holding.
  • Optimal Asset Management first reported a position in Neurocrine Biosciences in Q1 2020 and has held it in 7 quarters since.
  • Optimal Asset Management's Neurocrine Biosciences position peaked at $2.21M in Q2 2021.
  • 395 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2021.

Based on Optimal Asset Management's 13F filing for Q3 2021, filed 15 Nov 2021.